Chemotherapy drug shortages put young patients at risk; restrictions and challenges cause concerns of a rise in teen births; at least 28 companies failed to prove sufficient product testing for cough syrups.
A shortage of chemotherapy drugs used to treat pediatric cancers, including vinblastine, dacarbazine, and methotrexate, has created a crisis for children with cancer in the United States, according to NBC News. While some improvements have been seen in shortages of cancer drugs for adults, the situation for pediatric cancer patients remains dire. This shortage forces doctors to use less effective alternatives or delay treatment, putting young lives at risk and causing added distress for families. Efforts are needed to address the systemic issues causing these shortages and prioritize the well-being of pediatric cancer patients, clinicians and advocates say.
After decades of decline, the rate of teen births in the United States appears to be leveling off, and advocates are concerned that it may soon increase, according to KFF Health News. Factors including the Supreme Court's decision to strike down federal protections for abortion rights, opposition to sex education, and the impact of the COVID-19 pandemic on youth mental health could contribute to this trend. Limited access to abortion and contraception, along with the challenges of teenage pregnancy and motherhood, further compound the issue.
The FDA has increased scrutiny of ingredient testing in health care products following hundreds of deaths overseas related to contaminated cough syrups, according to Reuters. At least 28 companies have received reprimands from the FDA this year for insufficient testing of ingredients used in OTC drugs and consumer products, particularly for toxins like ethylene glycol and diethylene glycol. This crackdown, including more stringent testing requirements for individual ingredient containers, aims to prevent contaminated products from entering the US market.
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Perioperative Nivolumab Boosts NSCLC Survival: CheckMate 77T Trial
May 16th 2024This interim analysis of the CheckMate 77T trial, outcomes were compared between adult patients receiving neoadjuvant nivolumab plus chemotherapy or neoadjuvant chemotherapy plus placebo for resectable non–small cell lung cancer (NSCLC).
Read More